Glenmark Pharmaceuticals is currently trading at Rs. 689.50, up by 6.25 points or 0.91% from its previous closing of Rs. 683.25 on the BSE.
The scrip opened at Rs. 685.00 and has touched a high and low of Rs. 699.40 and Rs. 685.00 respectively. So far 1456 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 699.40 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.
Last one week high and low of the scrip stood at Rs. 699.40 and Rs. 643.70 respectively. The current market cap of the company is Rs. 19279.14 crore.
The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 37.55% and 15.91% respectively.
Glenmark Pharmaceuticals’ subsidiary -- Glenmark Arzneimittel GmbH has secured marketing authorization in Germany for Fluticasone/Salmeterol dry powder inhaler (DPI), a generic version of GlaxoSmithKline’s Seretide Accuhaler. Fluticasone/Salmeterol DPI is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark will sell the product in Germany under the name ‘Salflutin’.
Earlier, the company had entered into a strategic development and licensing agreement with Celon Pharma S.A. (Celon) in 2015 to develop and market generic Fluticasone/Salmeterol DPI in 15 European countries.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
